

Global GLP-1 Analogues Market

<https://marketpublishers.com/r/G1A916C7E178EN.html>

Date: December 2025

Pages: 85

Price: US\$ 2,950.00 (Single User License)

ID: G1A916C7E178EN

Abstracts

Summary:

This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.

The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.

Report Scope

This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.

The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.

The report aims to:

Analyze the market for GLP-1 analogues.

Analyze the global market size and market segments.

Understand market constraints and drivers.

Provide detailed market forecasts for 2030.

Assess market share, competitiveness and industry structure.

Identify potential long-term impacts on the GLP-1 analogue market.

Report Includes

An overview of the current and future global markets for GLP-1 analogues

In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030

Estimates of the size and revenue prospects of the global market, along with a market share analysis by route of administration, indication and region

Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors

An analysis of patents, emerging trends and developments in the industry

Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Profiles of the leading companies

Contents

CHAPTER 1 EXECUTIVE SUMMARY

- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion

CHAPTER 2 MARKET OVERVIEW

- Overview
- Analysis of Macroeconomic Factors
- Impact of U.S. Tariffs on the Pharmaceutical Industry
- Healthcare Expenditure
- Market Demand and Demographics
- Porter's Five Forces Analysis
- Bargaining Power of Buyers (High)
- Bargaining Power of Suppliers (Moderate to High)
- Potential for New Entrants (Low)
- Threat of Substitutes (Moderate)
- Competitiveness in the Industry (High)

CHAPTER 3 MARKET DYNAMICS

- Market Dynamics
- Market Drivers
- Increasing Cases of Diabetes and Obesity
- Increasing Awareness of Diagnosis and Treatment Options for Diabetes
- Strong R&D Pipeline
- Market Restraints
- Product Failure
- High Barriers for New Entrants
- Market Opportunities
- Extended Therapeutic Uses

Integration in Telehealth and Weight Management Program

CHAPTER 4 REGULATORY LANDSCAPE

Regulatory Dynamics

U.S.

Europe

Japan

China

CHAPTER 5 EMERGING TECHNOLOGIES AND PIPELINE ANALYSIS

Emerging Trends/Technologies

Next-Generation Multi-Receptor Agonists

Innovative Drug Delivery Methods

Expanded Therapeutic Indications

Pipeline Analysis

Key Takeaways

Patent Analysis

Key Takeaways

CHAPTER 6 MARKET SEGMENT ANALYSIS

Segmentation Breakdown

Global GLP-1 Analogues Market by Route of Administration

Key Takeaways

Injectable

Oral

Geographic Breakdown

Global GLP-1 Analogue Market by Region

Key Takeaways

North America

Europe

Asia-Pacific

South America

Middle East and Africa

CHAPTER 7 COMPETITIVE INTELLIGENCE

Key Takeaways
Competitive Landscape
Company Share Analysis

CHAPTER 8 SUSTAINABILITY IN GLP-1 ANALOGUES: ESG PERSPECTIVE

Introduction to ESG
Sustainability in the GLP-1 Analogue Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
Conclusion

CHAPTER 9 APPENDIX

Methodology
Sources
Abbreviations
Company Profiles
HANSOH PHARMACEUTICAL GROUP CO. LTD.
LILLY USA LLC.
NOVO NORDISK A/S
SANOFI
SHANGHAI BENEMAE PHARMACEUTICAL CORP.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players

List Of Tables

LIST OF TABLES

Summary Table : Global Market for GLP-1 Analogues, by Region, Through 2030

Table 1 : Global Health Expenditure, by Selected Country, 2021–2023

Table 2 : Worldwide Diabetic Adult Population , by Region, 2000–2050(Thousands)

Table 3 : FDA-Approved GLP-1 Receptor Agonists

Table 4 : Selected Clinical Trials for GLP-1 Receptor Agonists in Phases 3 and 4

Table 5 : Selected Granted Patents Related to GLP-1 Analogues, 2022–2024

Table 6 : Global Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 7 : Global Market for Injectable GLP-1 Analogues, by Region, Through 2030

Table 8 : Global Market for Oral GLP-1 Analogues, by Region, Through 2030

Table 9 : Global Market for GLP-1 Analogues, by Region, Through 2030

Table 10 : North American Diabetes Statistics and Prevalence, 2011–2050

Table 11 : North American Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 12 : North American Market for GLP-1 Analogues, by Country, Through 2030

Table 13 : European Diabetes Statistics and Prevalence, 2011–2050

Table 14 : European Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 15 : European Market for GLP-1 Analogues, by Country, Through 2030

Table 16 : South East Asian Diabetes Statistics and Prevalence, 2011–2050

Table 17 : Asia-Pacific Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 18 : Asia-Pacific Market for GLP-1 Analogues, by Country, Through 2030

Table 19 : South and Central American Diabetes Statistics and Prevalence, 2011–2050

Table 20 : South American Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 21 : South American Market for GLP-1 Analogues, by Country, Through 2030

Table 22 : Middle East and North Africa Diabetes Statistics and Prevalence, 2011–2050

Table 23 : MEA Market for GLP-1 Analogues, by Route of Administration, Through 2030

Table 24 : MEA Market for GLP-1 Analogues, by Sub-Region, Through 2030

Table 25 : Product Revenue, by Company, 2023 and 2024

Table 26 : Information Sources for this Report

Table 27 : Abbreviations Used in this Report

Table 28 : Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot

Table 29 : Hansoh Pharmaceutical Group Co. Ltd.: Financial Performance, FY 2023

and 2024

Table 30 : Hansoh Pharmaceutical Group Co. Ltd.: Product Portfolio

Table 31 : Hansoh Pharmaceutical Group Co. Ltd.: News/Key Developments, 2025

Table 32 : Lilly USA LLC.: Company Snapshot

Table 33 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024

Table 34 : Lilly USA LLC.: Product Portfolio

Table 35 : Lilly USA LLC.: News/Key Developments, 2025

Table 36 : Novo Nordisk A/S: Company Snapshot

Table 37 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024

Table 38 : Novo Nordisk A/S: Product Portfolio

Table 39 : Novo Nordisk A/S: News/Key Developments, 2023–2025

Table 40 : Sanofi: Company Snapshot

Table 41 : Sanofi: Financial Performance, FY 2023 and 2024

Table 42 : Sanofi: Product Portfolio

Table 43 : Sanofi: News/Key Developments, 2024

Table 44 : Shanghai Benemae Pharmaceutical Corp.: Company Snapshot

Table 45 : Shanghai Benemae Pharmaceutical Corp.: Product Portfolio

Table 46 : Shanghai Benemae Pharmaceutical Corp.: News/Key Developments, 2023

Table 47 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 48 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024

Table 49 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 50 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024 and 2025

Table 51 : Few Emerging Players in the GLP1 Analogue Market

List Of Figures

LIST OF FIGURES

- Summary Figure : Global Market Shares of GLP-1 Analogues, by Region, 2024
- Figure 1 : Porter's Five Forces Analysis of the GLP-1 Analogue Market
- Figure 2 : Market Dynamics of GLP-1 Analogues
- Figure 3 : Clinical Trial Studies of GLP-1 Drugs, by Trial Phase, 2022–2025*
- Figure 4 : Global Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 5 : Global Market Shares of Injectable GLP-1 Analogues, by Region, 2024
- Figure 6 : Global Market Shares of Oral GLP-1 Analogues, by Region, 2024
- Figure 7 : Global Market Shares of GLP-1 Analogues, by Region, 2024
- Figure 8 : North American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 9 : North American Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 10 : European Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 11 : European Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 12 : Asia-Pacific Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 13 : Asia-Pacific Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 14 : South American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 15 : South American Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 16 : MEA Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 17 : MEA Market Shares of GLP-1 Analogues, by Sub-Region, 2024
- Figure 18 : Global Market Shares of GLP-1 Analogues, by Company, 2024
- Figure 19 : Pillars of ESG
- Figure 20 : Advantages of ESG for Companies
- Figure 21 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
- Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
- Figure 23 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2024
- Figure 24 : SANOFI: Revenue Share, by Country/Region, FY 2024
- Figure 25 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024
- Figure 26 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024

I would like to order

Product name: Global GLP-1 Analogues Market

Product link: <https://marketpublishers.com/r/G1A916C7E178EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1A916C7E178EN.html>